IJLH:定量分析成年1型冯•威利斯布兰德病患者的去氨加压素(DDAVP)反应

2019-07-22 不详 MedSci原创

1型血管性血友病(VWD)患者血液中的血管性血友病因子(VWF)会出现明显减少。去氨加压素(DDAVP)常用于提高这些患者的VWF血液水平。然而,并不是所有的1型VWD患者都对DDAVP治疗有效果。本研究试图比较DDAVP给药后不同时间点的VIII因子、VWF抗原(VWF抗原:Ag)、VWF ristocetin辅因子(VWF:RCo)和纤维蛋白原水平。研究人员回顾性分析是由一个机构对89名1型血

1血管性血友病(VWD)患者血液中的血管性血友病因子(VWF)会出现明显减少。去氨加压素(DDAVP)常用于提高这些患者的VWF血液水平。然而,并不是所有的1VWD患者都对DDAVP治疗有效果。本研究试图比较DDAVP给药后不同时间点的VIII因子、VWF抗原(VWF抗原:Ag)VWF ristocetin辅因子(VWF:RCo)和纤维蛋白原水平。

研究人员回顾性分析是由一个机构对891型血管性血友病患者接受单剂量静脉DDAVP0.3μg /公斤)。在DDAVP给药结束后306090120分钟分别测定因子VIIIVWF:AgVWF:RCo和纤维蛋白原水平。

研究发现,相比各自的基线值(71 IU / dL, 54 IU / dL, 54 IU / dL)30 (175 IU / dL 111 IU / dL 127 IU / dL)60 (218 IU / dL 138 IU / dL 139 IU / dL)90 (212 IU / dL 134 IU / dL 130 IU / dL)分钟时间点中等水平的因子,VWF: Ag)VWF有数明显升高(P < 0.001)。在60分钟时,96%的受试者出现应答反应,但有三名受试者在任何时间点都没有应答。

研究表明,测定因子VIIIVWF:AgVWF:RCo的水平,且最好在DDAVP输注后60分钟,足以在DDAVP试验中确认患者为应答者。减少测量时间点的数量将大大节省患者及其提供者的成本和时间。

原始出处:

Achuta K. Guddati, Rachel P. Rosovsky ,Quantitative analysis of desmopressin (DDAVP) response in adult patients with type 1 von Willebrand disease

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1933369, encodeId=c5631933369e1, content=<a href='/topic/show?id=eaf54598041' target=_blank style='color:#2F92EE;'>#定量分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45980, encryptionId=eaf54598041, topicName=定量分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Mon Mar 09 07:51:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009502, encodeId=10f92009502d6, content=<a href='/topic/show?id=1e203e249c3' target=_blank style='color:#2F92EE;'>#去氨加压素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37249, encryptionId=1e203e249c3, topicName=去氨加压素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Jun 06 18:51:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784140, encodeId=f1c91e84140c5, content=<a href='/topic/show?id=e9b35e65cc' target=_blank style='color:#2F92EE;'>#DDAVP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5765, encryptionId=e9b35e65cc, topicName=DDAVP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Mon Jul 06 05:51:00 CST 2020, time=2020-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992053, encodeId=241e19920533d, content=<a href='/topic/show?id=11b13296e8e' target=_blank style='color:#2F92EE;'>#加压素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32967, encryptionId=11b13296e8e, topicName=加压素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Thu Mar 12 00:51:00 CST 2020, time=2020-03-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1933369, encodeId=c5631933369e1, content=<a href='/topic/show?id=eaf54598041' target=_blank style='color:#2F92EE;'>#定量分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45980, encryptionId=eaf54598041, topicName=定量分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Mon Mar 09 07:51:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009502, encodeId=10f92009502d6, content=<a href='/topic/show?id=1e203e249c3' target=_blank style='color:#2F92EE;'>#去氨加压素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37249, encryptionId=1e203e249c3, topicName=去氨加压素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Jun 06 18:51:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784140, encodeId=f1c91e84140c5, content=<a href='/topic/show?id=e9b35e65cc' target=_blank style='color:#2F92EE;'>#DDAVP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5765, encryptionId=e9b35e65cc, topicName=DDAVP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Mon Jul 06 05:51:00 CST 2020, time=2020-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992053, encodeId=241e19920533d, content=<a href='/topic/show?id=11b13296e8e' target=_blank style='color:#2F92EE;'>#加压素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32967, encryptionId=11b13296e8e, topicName=加压素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Thu Mar 12 00:51:00 CST 2020, time=2020-03-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1933369, encodeId=c5631933369e1, content=<a href='/topic/show?id=eaf54598041' target=_blank style='color:#2F92EE;'>#定量分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45980, encryptionId=eaf54598041, topicName=定量分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Mon Mar 09 07:51:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009502, encodeId=10f92009502d6, content=<a href='/topic/show?id=1e203e249c3' target=_blank style='color:#2F92EE;'>#去氨加压素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37249, encryptionId=1e203e249c3, topicName=去氨加压素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Jun 06 18:51:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784140, encodeId=f1c91e84140c5, content=<a href='/topic/show?id=e9b35e65cc' target=_blank style='color:#2F92EE;'>#DDAVP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5765, encryptionId=e9b35e65cc, topicName=DDAVP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Mon Jul 06 05:51:00 CST 2020, time=2020-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992053, encodeId=241e19920533d, content=<a href='/topic/show?id=11b13296e8e' target=_blank style='color:#2F92EE;'>#加压素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32967, encryptionId=11b13296e8e, topicName=加压素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Thu Mar 12 00:51:00 CST 2020, time=2020-03-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1933369, encodeId=c5631933369e1, content=<a href='/topic/show?id=eaf54598041' target=_blank style='color:#2F92EE;'>#定量分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45980, encryptionId=eaf54598041, topicName=定量分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Mon Mar 09 07:51:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009502, encodeId=10f92009502d6, content=<a href='/topic/show?id=1e203e249c3' target=_blank style='color:#2F92EE;'>#去氨加压素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37249, encryptionId=1e203e249c3, topicName=去氨加压素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Jun 06 18:51:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784140, encodeId=f1c91e84140c5, content=<a href='/topic/show?id=e9b35e65cc' target=_blank style='color:#2F92EE;'>#DDAVP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5765, encryptionId=e9b35e65cc, topicName=DDAVP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Mon Jul 06 05:51:00 CST 2020, time=2020-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992053, encodeId=241e19920533d, content=<a href='/topic/show?id=11b13296e8e' target=_blank style='color:#2F92EE;'>#加压素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32967, encryptionId=11b13296e8e, topicName=加压素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Thu Mar 12 00:51:00 CST 2020, time=2020-03-12, status=1, ipAttribution=)]
    2020-03-12 fyxzlh

相关资讯

Int J Oral Max Surg:遗传性出血患者拔牙术后并发症的长达十年的研究

拔牙对于止血机制是一个挑战。遗传性出血性疾病患者拔牙术后出血延长,甚至威胁生命安全。我们提倡术前和术后采用凝血因子替代品或系统去氨加压素(ddAVP),以预防出血并发症。